Jyong Biotech Ltd. Ordinary Shares - Asset Resilience Ratio
Jyong Biotech Ltd. Ordinary Shares (MENS) has an Asset Resilience Ratio of 44.80% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2023)
This chart shows how Jyong Biotech Ltd. Ordinary Shares's Asset Resilience Ratio has changed over time. See how financially flexible is Jyong Biotech Ltd. Ordinary Shares to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Jyong Biotech Ltd. Ordinary Shares's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MENS company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $16.88 Million | 44.8% |
| Total Liquid Assets | $16.88 Million | 44.80% |
Asset Resilience Insights
- Very High Liquidity: Jyong Biotech Ltd. Ordinary Shares maintains exceptional liquid asset reserves at 44.80% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Jyong Biotech Ltd. Ordinary Shares Industry Peers by Asset Resilience Ratio
Compare Jyong Biotech Ltd. Ordinary Shares's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Prostemics Co. Ltd
KQ:203690 |
Biotechnology | 0.31% |
|
ORUM
KQ:475830 |
Biotechnology | 82.74% |
|
TELIX Pharmaceuticals Ltd
AU:TLX |
Biotechnology | 32.29% |
|
TG Therapeutics Inc
NASDAQ:TGTX |
Biotechnology | 4.72% |
|
Green Cross Holdings Preference Shares
KO:005257 |
Biotechnology | 0.50% |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT |
Biotechnology | 33.70% |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5 |
Biotechnology | 41.67% |
|
Cybin Inc
NEO:CYBN |
Biotechnology | 0.21% |
Annual Asset Resilience Ratio for Jyong Biotech Ltd. Ordinary Shares (2020–2023)
The table below shows the annual Asset Resilience Ratio data for Jyong Biotech Ltd. Ordinary Shares.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $8.25 Million | -- |
| 2022-12-31 | 1.07% | $94.00K | $8.74 Million | -18.37pp |
| 2021-12-31 | 19.44% | $1.83 Million | $9.43 Million | +14.27pp |
| 2020-12-31 | 5.17% | $664.00K | $12.84 Million | -- |
About Jyong Biotech Ltd. Ordinary Shares
Jyong Biotech Ltd., a science-driven biotechnology company, develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder … Read more